Analysis of differential secondary effects of novel rexinoids: Select rexinoid X receptor ligands demonstrate differentiated side effect profiles

Pamela Marshall, Peter Jurutka, Carl Wagner, Arjan van der Vaart, Ichiro Kaneko, Pedro I. Chavez, Ning Ma, Jaskaran S. Bhogal, Pritika Shahani, Johnathon C. Swierski, Mairi Macneill

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In order to determine the feasibility of utilizing novel rexinoids for chemotherapeutics and as potential treatments for neurological conditions, we undertook an assessment of the side effect profile of select rexinoid X receptor (RXR) analogs that we reported previously. We assessed pharmacokinetic profiles, lipid and thyroid-stimulating hormone (TSH) levels in rats, and cell culture activity of rexinoids in sterol regulatory element-binding protein (SREBP) induction and thyroid hormone inhibition assays. We also performed RNA sequencing of the brain tissues of rats that had been dosed with the compounds. We show here for the first time that potent rexinoid activity can be uncoupled from drastic lipid changes and thyroid axis variations, and we propose that rexinoids can be developed with improved side effect profiles than the parent compound, bexarotene (1).

Original languageEnglish (US)
Pages (from-to)1-19
Number of pages19
JournalPharmacology Research and Perspectives
Volume3
Issue number2
DOIs
StatePublished - Mar 1 2015

Fingerprint

Sterol Regulatory Element Binding Proteins
Ligands
RNA Sequence Analysis
Lipids
Thyrotropin
Thyroid Hormones
Thyroid Gland
Pharmacokinetics
Cell Culture Techniques
Brain
bexarotene

Keywords

  • Bexarotene
  • Lipids
  • Rexinoids
  • RXR
  • Thyroid

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Neurology

Cite this

Analysis of differential secondary effects of novel rexinoids : Select rexinoid X receptor ligands demonstrate differentiated side effect profiles. / Marshall, Pamela; Jurutka, Peter; Wagner, Carl; van der Vaart, Arjan; Kaneko, Ichiro; Chavez, Pedro I.; Ma, Ning; Bhogal, Jaskaran S.; Shahani, Pritika; Swierski, Johnathon C.; Macneill, Mairi.

In: Pharmacology Research and Perspectives, Vol. 3, No. 2, 01.03.2015, p. 1-19.

Research output: Contribution to journalArticle

Marshall, Pamela ; Jurutka, Peter ; Wagner, Carl ; van der Vaart, Arjan ; Kaneko, Ichiro ; Chavez, Pedro I. ; Ma, Ning ; Bhogal, Jaskaran S. ; Shahani, Pritika ; Swierski, Johnathon C. ; Macneill, Mairi. / Analysis of differential secondary effects of novel rexinoids : Select rexinoid X receptor ligands demonstrate differentiated side effect profiles. In: Pharmacology Research and Perspectives. 2015 ; Vol. 3, No. 2. pp. 1-19.
@article{51e947278c7b4df58123e4829248a0ae,
title = "Analysis of differential secondary effects of novel rexinoids: Select rexinoid X receptor ligands demonstrate differentiated side effect profiles",
abstract = "In order to determine the feasibility of utilizing novel rexinoids for chemotherapeutics and as potential treatments for neurological conditions, we undertook an assessment of the side effect profile of select rexinoid X receptor (RXR) analogs that we reported previously. We assessed pharmacokinetic profiles, lipid and thyroid-stimulating hormone (TSH) levels in rats, and cell culture activity of rexinoids in sterol regulatory element-binding protein (SREBP) induction and thyroid hormone inhibition assays. We also performed RNA sequencing of the brain tissues of rats that had been dosed with the compounds. We show here for the first time that potent rexinoid activity can be uncoupled from drastic lipid changes and thyroid axis variations, and we propose that rexinoids can be developed with improved side effect profiles than the parent compound, bexarotene (1).",
keywords = "Bexarotene, Lipids, Rexinoids, RXR, Thyroid",
author = "Pamela Marshall and Peter Jurutka and Carl Wagner and {van der Vaart}, Arjan and Ichiro Kaneko and Chavez, {Pedro I.} and Ning Ma and Bhogal, {Jaskaran S.} and Pritika Shahani and Swierski, {Johnathon C.} and Mairi Macneill",
year = "2015",
month = "3",
day = "1",
doi = "10.1002/prp2.122",
language = "English (US)",
volume = "3",
pages = "1--19",
journal = "Pharmacology Research and Perspectives",
issn = "2052-1707",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Analysis of differential secondary effects of novel rexinoids

T2 - Select rexinoid X receptor ligands demonstrate differentiated side effect profiles

AU - Marshall, Pamela

AU - Jurutka, Peter

AU - Wagner, Carl

AU - van der Vaart, Arjan

AU - Kaneko, Ichiro

AU - Chavez, Pedro I.

AU - Ma, Ning

AU - Bhogal, Jaskaran S.

AU - Shahani, Pritika

AU - Swierski, Johnathon C.

AU - Macneill, Mairi

PY - 2015/3/1

Y1 - 2015/3/1

N2 - In order to determine the feasibility of utilizing novel rexinoids for chemotherapeutics and as potential treatments for neurological conditions, we undertook an assessment of the side effect profile of select rexinoid X receptor (RXR) analogs that we reported previously. We assessed pharmacokinetic profiles, lipid and thyroid-stimulating hormone (TSH) levels in rats, and cell culture activity of rexinoids in sterol regulatory element-binding protein (SREBP) induction and thyroid hormone inhibition assays. We also performed RNA sequencing of the brain tissues of rats that had been dosed with the compounds. We show here for the first time that potent rexinoid activity can be uncoupled from drastic lipid changes and thyroid axis variations, and we propose that rexinoids can be developed with improved side effect profiles than the parent compound, bexarotene (1).

AB - In order to determine the feasibility of utilizing novel rexinoids for chemotherapeutics and as potential treatments for neurological conditions, we undertook an assessment of the side effect profile of select rexinoid X receptor (RXR) analogs that we reported previously. We assessed pharmacokinetic profiles, lipid and thyroid-stimulating hormone (TSH) levels in rats, and cell culture activity of rexinoids in sterol regulatory element-binding protein (SREBP) induction and thyroid hormone inhibition assays. We also performed RNA sequencing of the brain tissues of rats that had been dosed with the compounds. We show here for the first time that potent rexinoid activity can be uncoupled from drastic lipid changes and thyroid axis variations, and we propose that rexinoids can be developed with improved side effect profiles than the parent compound, bexarotene (1).

KW - Bexarotene

KW - Lipids

KW - Rexinoids

KW - RXR

KW - Thyroid

UR - http://www.scopus.com/inward/record.url?scp=84991365057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991365057&partnerID=8YFLogxK

U2 - 10.1002/prp2.122

DO - 10.1002/prp2.122

M3 - Article

AN - SCOPUS:84991365057

VL - 3

SP - 1

EP - 19

JO - Pharmacology Research and Perspectives

JF - Pharmacology Research and Perspectives

SN - 2052-1707

IS - 2

ER -